Dievini

Dievini

Dietmar Hopp founded Dievini in 2007 to manage the wealth generated from his role as a co-founder of SAP, the Walldorf-based enterprise software giant. Rather than diluting his exposure across a generic multi-asset pool, Hopp structured the office to concentrate on biotechnology, healthtech, and advanced software — sectors where he could apply both patient capital and his own technical operating experience. The firm operates from Walldorf, maintaining close geographic and cultural ties to the German Mittelstand and the country's university research ecosystems. Dievini's deployment model favors direct equity stakes in growth-stage life-sciences and technology companies, often serving as an anchor investor capable of writing substantial checks that bridge early institutional rounds. Confirmed portfolio positions include CureVac, the mRNA technology company that went public on Nasdaq in 2020, and a historic early investment in BioNTech, the Mainz-based firm that co-developed the Pfizer-BioNTech COVID-19 vaccine. The firm also holds positions in digital health and AI-driven drug discovery platforms, maintaining a portfolio concentrated enough that each position can influence scientific outcomes. Its geographic focus centers on Germany and broader continental Europe, with selective exposure to US-based biotech through co-investment networks. Dievini does not publicly report assets under management, but the concentrated nature of its portfolio and the multi-billion-euro valuations of its headline holdings suggest a commitment well into the billions (Altss estimate). The firm operates with a lean internal team, relying on Hopp's direct involvement and a network of scientific advisors rather than a large in-house investment staff. Adjacent to the investment vehicle, Hopp established the Dietmar Hopp Stiftung, a major German philanthropic foundation focused on sports, education, and medical research, creating a clear separation between the family's endowment-style giving and the return-oriented investment activities at Dievini. In June 2022, CureVac and GSK announced a restructuring of their COVID-19 collaboration, a corporate event that directly reshaped one of Dievini's most significant public-market exposures. Dievini's structural edge lies in its single-decision-maker architecture paired with a willingness to absorb scientific risk that institutional limited partners often cannot hold. Unlike a traditional venture fund, the firm has no external capital to return on a fixed timeline, allowing it to support portfolio companies through multi-year clinical trials without forced exit pressure. This governance structure — Dietmar Hopp as the sole economic principal with direct operating experience in a company that transformed enterprise computing — produces an investment vehicle that behaves more like a hybrid between a family office and a permanent-capital venture firm.